Brokerages Set Aridis Pharmaceuticals Inc (ARDS) Price Target at $27.50
Shares of Aridis Pharmaceuticals Inc (NASDAQ:ARDS) have earned an average recommendation of “Buy” from the seven research firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $27.50.
ARDS has been the subject of a number of research analyst reports. Zacks Investment Research upgraded Aridis Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, January 14th. Northland Securities restated a “buy” rating and set a $40.00 price objective on shares of Aridis Pharmaceuticals in a report on Friday, March 29th. Finally, Maxim Group restated a “buy” rating and set a $25.00 price objective on shares of Aridis Pharmaceuticals in a report on Monday, April 1st.
Shares of ARDS stock traded up $0.63 on Tuesday, reaching $10.20. 302 shares of the stock were exchanged, compared to its average volume of 3,766. The company has a market cap of $82.69 million and a price-to-earnings ratio of -1.46. Aridis Pharmaceuticals has a 1-year low of $7.59 and a 1-year high of $13.85.
Aridis Pharmaceuticals Company Profile
Aridis Pharmaceuticals Inc, a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S.
Read More: 52-Week High/Low Prices For Stock Selection
Receive News & Ratings for Aridis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aridis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.